Foundations and Adaptive Learning
Begin with the Foundations Modules, “Patient Points” and “Clinical Applications,” followed by the Adaptive Learning Module.
Complete Foundations Activity
GENOM Foundations: Complete Patient Points and Clinical Applications
Complete Adaptive Learning
Complete Lymphoma Adaptive Learning Module
Complete Evaluation
Complete the evaluation by clicking the link below to claim your contact hour
Activity Information
This activity is intended for hematologists, hematologists/oncologists, medical oncologists, nurses, physician assistants, and nurse practitioners caring for patients with blood cancers.
Genomic profiling is widely recognized as a key way to identify strategies for treating hematologic (and other) cancers. However, there is a significant disconnect between scientific evidence and hematologist/oncologist knowledge, confidence, and practice. As a wealth of new information continues to emerge, it is essential that hematologists/oncologists have a strong foundational understanding of genomics and its practical applications.
- Review genomic principles, terminology, technologies, and applications
- Describe available genomic tests for diagnosis of hematologic malignancies and relevant premalignant conditions
- Interpret test results and select appropriate therapeutic agents to manage specific hematologic malignancies
- Develop strategies to explain tests and their implications to patients and caregivers
PLANNING COMMITTEE
Jennifer Brown, MD, PhD (Planning Committee Chair)
Director, CLL Center of the Division of Hematologic Malignancies
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA
Rafael Fonseca, MD
Director, Mayo Clinic Comprehensive Cancer Center
Director for Innovation and Transformational Relationships
Getz Family Professor of Cancer, Distinguished Mayo Investigator
Phoenix, AZ
Neha Mehta-Shah, MD, MSCI
Assistant Professor, Department of Medicine
Division of Medical Oncology
Washington University in St. Louis School of Medicine
St. Louis, MO
Alice Mims, MD
Acute Leukemia Clinical Research Director
Assistant Professor, Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, OH
Nina Fragale, NP
Internal Medicine, Medical Oncology
Washington University in St. Louis School of Medicine
St. Louis, MO
FACULTY
Mary Albrethsen, APRN-CNP
Nurse Practitioner
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, OH
Rafael Fonseca, MD
Director, Mayo Clinic Comprehensive Cancer Center
Director for Innovation and Transformational Relationships
Getz Family Professor of Cancer, Distinguished Mayo Investigator
Phoenix, AZ
Ann S. LaCasce, MD, MMSc
Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
Fellowship Program in Hematology/Oncology Chair
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Robert Coleman Lindsley, Jr., MD, PhD
Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Neha Mehta-Shah, MD, MSCI
Assistant Professor, Department of Medicine
Division of Medical Oncology
Washington University in St. Louis School of Medicine
St. Louis, MO
Alice Mims, MD
Acute Leukemia Clinical Research Director
Assistant Professor, Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, OH
Darci L. Zblewski, APRN, CNP
Nurse Practitioner
Mayo Clinic
Rochester, MN
Continuing Education (CE) Credit
In this activity, you will complete 3 modules to fulfill a minimum of 1.0 Nursing CE contact hour. You will begin by completing the 2 Foundations modules, followed by the 1 interactive Clinical Applications module.
Nurses
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.
The France Foundation participated in the development of this activity in collaboration with the American Society of Hematology and The Leukemia & Lymphoma Society. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The American Society of Hematology (ASH), The Leukemia & Lymphoma Society (LLS), and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. ASH, LLS, and TFF resolve all conflict of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, ASH, LLS, and TFF seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ASH, LLS, and TFF are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
2. Astellas Pharmaceuticals, Ryvu Therapeutics, Servier Pharmaceuticals, Syndax Pharmaceuticals
3. Daiichi Sankyo, Jazz Pharmaceuticals
2. Advisory Board Member
3. Data and Safety Monitoring Board Member
Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
2. Up to Date
2. Patent & Royalties
2. Acerta/AstraZeneca, BeiGene, Genzyme, Gilead, iOnctura, Loxo, MEI Pharma, Secura Bio, and TG Therapeutics
3. Acerta/AstraZeneca, BeiGene
4. Pfizer
2. Contract Research
3. Advisory Board
4. Honoraria
Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
2. AstraZeneca, Bristol-Myers Squibb, C4 Therapeutics, Celgene, Corvus, Daiichi Sankyo, Dizal Pharmaceuticals, Genentech, Innate Pharmaceuticals, Secura Bio, Verastem Pharmaceuticals
2. Research
• Daiichi Sankyo non-CE consulting ended on 11/2021
• Secura Bio non-CE consulting ended in 12/2021
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair
Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
2. Amgen, Cylene, Onyx, Proteolix, and Sanofi. He owns stock in Adaptive Biotechnologies
3. FISH for myeloma prognosis
4. Mayo Clinic
5. Adaptive Biotechnologies, Caris Life Science, Oncomyx, and Oncotracker
6. Adaptive Biotechnologies
2. Research
3. Patent
4. Royalties
5. Advisory Board Member
6. Equity/Stock ownership in publicly held commercial entity
Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
2. Jazz Pharmaceuticals
2. Research
TFF, ASH, and LLS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ASH, and LLS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
This activity is supported by educational grants from AbbVie, Astellas, Daiichi Sankyo, Illumina, and Pharmacyclics.
The American Society of Hematology, The Leukemia & Lymphoma Society, and The France Foundation present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ASH, LLS, TFF, and the commercial supporter(s) assume no liability for the information herein.
- The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission.
ASH, LLS, and TFF maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Additional information regarding The France Foundation’s Privacy Policy can be viewed at https://www.francefoundation.com/privacy.
Activity Title: Genomics Essentials in Hematologic Malignancies (GENOM): Foundations and Adaptive Learning
Topics: Foundations: Patient Points and Clinical Applications
Lymphoma Adaptive Learning Module
AML/MDS Adaptive Learning Module
Technical Requirements
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox, and Safari browsers.
Additionally, this site and its activities are best viewed using the latest operating system for your device.
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
